Apogee Therapeutics, Inc.
APGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $3 | $1 | $1 |
| - Cash | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 |
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| EBITDA | -$0 | -$0 | -$0 |
| % Margin | – | – | – |
| Net Income | -$0 | -$0 | -$0 |
| % Margin | – | – | – |
| EPS Diluted | -3.3 | -1.66 | -0.79 |
| % Growth | -98.8% | -110.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 |